Dexamethasone study shows promising results for treating COVID-19 patients
The New England Journal of Medicine last week released a study showing that the use of dexamethasone resulted in a lower, 28-day mortality rate among patients receiving invasive ventilation or oxygen.
The study indicated lower incidence of death among 2,104 patients treated with dexamethasone, compared to 4,321 patients receiving usual care. However, results showed very little impact in patients not receiving respiratory support.
The Food and Drug Administration also recently updated its COVID-19 treatment guidelines for corticosteroids, including dexamethasone. FDA said such drugs can be used for up to 10 days in patients requiring supplemental oxygen, but not with those who are mechanically ventilated or do not require supplemental oxygen.
Related News Articles
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Headline
The National Institutes of Health Oct. 10 released results of a study that found that infection from COVID-19 in the first wave of the pandemic appeared to…